FARAN S.A. & STADA Arzneimittel AG collaboration announcement FARAN S.A. and STADA Arzneimittel AG are pleased to announce the launch of their collaboration in the field of Osteoporosis. More specifically, FARAN undertakes the promotion and distribution in the Greek market of the STADA Arzneimittel AG product MOVYMIA, the first Biosimilar Teriparatide of STADA Arzneimittel AG.
FARAN SA and SANDOZ member of the Novartis Group, after their successful collaboration, are pleased to announce the expansion of their cooperation, undertaking the promotion and distribution of another product with the active substance Epoetin alpha.
FARAN SA and NOVARTIS (Hellas) SA are pleased to announce the launch of their collaboration in the field of therapeutic oncology. More specifically, FARAN undertakes the promotion and distribution in the Greek market of the NOVARTIS products TYVERB (Lapatinib) and ZYKADIA (Ceritinib). TYVERB (Lapatinib) is indicated for the treatment of patients with metastatic breast cancer […]
Faran SA, one of the historical Pharmaceutical companies with a presence of more than 70 years in the Greek Pharmaceutical market, received the “2018 Pharmaceutical Sector Business Award” from the Internal Medicine Society of Greece, as an acknowledgement of the continuous contribution of Faran to the Healthcare sector and the public health.